EPISODE · Jan 20, 2019 · 43 MIN
Gilead Sciences Stock Analysis (Episode010)
from The DIY Investing Podcast · host Trey Henninger: Private Investor, Portfolio Manager, Business Strategist, and Value Investing Expert
Gilead Sciences is a biopharmaceutical company with a focus on treating and curing diseases. Their areas of focus include HIV, Hepatitis C, Oncology, Inflammation, and NASH. Gilead Sciences (GILD) Business Model Overview HIV Hepatitis C Oncology/Cancer Treatment (KITE) – Yescarta Inflammation - Filgotinib NASH (Liver disease) – Selonsertib Leading cause of liver transplants. Generally related to Obesity Durability Competition Quality and Growth Capital Allocation Value Potential Errors Conclusion Show Notes available at DIYInvesting.org The full show notes for this episode, including my outline for today's podcast, are available at https://www.diyinvesting.org/Episode6 Please review and rate the podcast If you enjoyed this podcast and found it helpful, please consider leaving me a review. On an iOS platform such as an iPhone or iPad, you can do so by following these steps: In your podcast app, click the search icon that looks like a magnifying glass in the bottom right-hand corner. Type "The DIY Investing" into the search bar. This podcast should be one of the first shows that display. Select the podcast show icon. Scroll down to the "Ratings & Reviews Section" and click on the button that says "Write a Review". Write a short one or two sentence review and give me a rating that matches how you feel about the podcast.
NOW PLAYING
Gilead Sciences Stock Analysis (Episode010)
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m